Study of nivolumab with chemo before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well the immunotherapy drug nivolumab (Opdivo) works when given with standard chemotherapy before surgery for people with a certain type of lung cancer that has not spread. It may help shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have non-small cell lung cancer that has not spread to other parts of the body
- Your tumor has a PD-L1 level of 1% or more (a protein found on some cancer cells)
- Your doctor has decided to treat you with nivolumab plus platinum chemotherapy before surgery
- You are willing to fill out questionnaires about your health and understand German
- You do not have another type of cancer that needs treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This trial looks at real-world outcomes in Taiwan for people with resectable non-small cell lung cancer (NSCLC) who get nivolumab combined with chemotherapy before surgery. It aims to understand how well this treatment works and how safe it is.
This trial tests whether two immunotherapy drugs (nivolumab and ipilimumab) given before surgery can help treat non-small cell lung cancer that is stage II to IIIA. It's for people whose tumors are removable and who haven't had prior cancer treatment.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.